CDTX
Cidara Therapeutics Inc

8,842
Mkt Cap
$2.36B
Volume
212.00
52W High
$121.21
52W Low
$12.10
PE Ratio
-8.36
CDTX Fundamentals
Price
$93.12
Prev Close
$96.16
Open
$97.74
50D MA
$81.53
Beta
0.61
Avg. Volume
1.04M
EPS (Annual)
-$26.46
P/B
4.32
Rev/Employee
$33,552.63
Loading...
Loading...
News
all
press releases
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
Zacks·17d ago
News Placeholder
More News
News Placeholder
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral
The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.
Stocktwits·18d ago
News Placeholder
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
Zacks·1mo ago
News Placeholder
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today
Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the firm confirmed that it is in talks with the Energy Department and GM over the $2.6 billion Thacker Pass project loan.
Stocktwits·1mo ago
News Placeholder
Cidara Therapeutics (CDTX) Upgraded to Buy: Here's What You Should Know
Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?
Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering
The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.
Stocktwits·4mo ago
News Placeholder
Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial
Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.
Stocktwits·4mo ago
News Placeholder
Cidara Therapeutics: A Strong Buy on Promising Trials and Strategic Milestones
Cidara Therapeutics (CDTX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer...
TipRanks Financial Blog·1y ago
News Placeholder
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX CDTX INVESTOR NOTICE: ROSEN, TOP...
PR Newswire·1y ago

Latest CDTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.